BioCardia

BCDANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$13.442 M

$0.89 -2.76%

Close of 6 Nov 2026

As of 6 Nov 2026, BioCardia (BCDA) has a market capitalization of $13.4M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$8.23M

Loss-making

Shares outstanding

15,138,782

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#145ScilexSCLX$14.3M
#146Dyadic InternationalDYAI$13.6M
#147BioCardiaBCDA$13.4M
#148TScan TherapeuticsTCRX$11.5M
#149Passage BIOPASG$11.1M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of BioCardia, worth $10.7K. Grants and option exercises are excluded.

Peter AltmanPresident and CEO$5.02K
5,400 shares at $0.93 on 17 Aug 2026 · filed 18 Aug 2026
Peter AltmanPresident and CEO$1.75K
1,900 shares at $0.92 on 13 Aug 2026 · filed 13 Aug 2026
Peter AltmanPresident and CEO$3.90K
5,000 shares at $0.78 on 29 Jul 2026 · filed 29 Jul 2026

What if BioCardia were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,865,201

Per share 2,100,688× higher

Bitcoin $1.53T

$100,922.78

Per share 113,665× higher

Apple $5.02T

$331,320.08

Per share 373,150× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for BioCardia are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.